

Special Issue

Radionuclide Therapy and Hybrid Imaging in Oncology

Message from the Guest Editors

This Special Issue addresses the role of radionuclides for diagnostic and therapeutic purposes in oncology. A variety of radionuclides have been introduced for hybrid imaging combining molecular imaging (i.e., single photon emission computed tomography (SPECT) or positron emission tomography (PET)) with data from morphological imaging (i.e., computer tomography (CT) and magnetic resonance imaging (MRI)). 18F-FDG PET/CT is the most frequently used form of hybrid imaging and has formed an integral part of diagnostic workup in oncology for several years.

Guest Editors

Dr. Amir Sabet

Department of Nuclear Medicine, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany

Prof. Dr. Frank Grünwald

Department of Nuclear Medicine, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany

Deadline for manuscript submissions

closed (29 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/91705

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)